Regeneron Pharmaceuticals, Inc. (TICKER: REGN) Benchmark And Performance Data

there are 4 of samples in the benchmark for Regeneron Pharmaceuticals, Inc. in year 2022 in 2022. The total inventory for Regeneron Pharmaceuticals, Inc. was $726,100,000.00 in 2017. The total inventory for Regeneron Pharmaceuticals, Inc. was $70,354,000.00 in 2013. The total inventory for Regeneron Pharmaceuticals, Inc. was $399,356,000.00 in 2016. The total inventory for Regeneron Pharmaceuticals, Inc. was $28,638,000.00 in 2012. The total inventory for Regeneron Pharmaceuticals, Inc. was $238,578,000.00 in 2015. The total inventory for Regeneron Pharmaceuticals, Inc. was $128,861,000.00 in 2014. The total inventory for Regeneron Pharmaceuticals, Inc. was $1,951,300,000.00 in 2021. The total inventory for Regeneron Pharmaceuticals, Inc. was $1,916,600,000.00 in 2020. The total inventory for Regeneron Pharmaceuticals, Inc. was $1,415,500,000.00 in 2019. The total inventory for Regeneron Pharmaceuticals, Inc. was $1,151,200,000.00 in 2018. The sales, general, and administrative (SGA) for Regeneron Pharmaceuticals, Inc. was $838,526,000.00 in 2015. The sales, general, and administrative (SGA) for Regeneron Pharmaceuticals, Inc. was $519,267,000.00 in 2014. The sales, general, and administrative (SGA) for Regeneron Pharmaceuticals, Inc. was $346,393,000.00 in 2013. The sales, general, and administrative (SGA) for Regeneron Pharmaceuticals, Inc. was $210,755,000.00 in 2012. The sales, general, and administrative (SGA) for Regeneron Pharmaceuticals, Inc. was $1,824,900,000.00 in 2021. The sales, general, and administrative (SGA) for Regeneron Pharmaceuticals, Inc. was $1,346,000,000.00 in 2020. The sales, general, and administrative (SGA) for Regeneron Pharmaceuticals, Inc. was $1,341,900,000.00 in 2019. The sales, general, and administrative (SGA) for Regeneron Pharmaceuticals, Inc. was $1,320,400,000.00 in 2017. The sales, general, and administrative (SGA) for Regeneron Pharmaceuticals, Inc. was $1,177,700,000.00 in 2016. The sales, general, and administrative (SGA) for Regeneron Pharmaceuticals, Inc. was $1,127,200,000.00 in 2018. The sales, general, and administrative (SGA) for Regeneron Pharmaceuticals, Inc. was $$2,116,000,000 in 2022. The revenue volatility for Regeneron Pharmaceuticals, Inc. was 40.97% in 2022. The market capitalization for Regeneron Pharmaceuticals, Inc. was $90,137,199,000.00 in 2019. The market capitalization for Regeneron Pharmaceuticals, Inc. was $89,339,482,565.00 in 2021. The market capitalization for Regeneron Pharmaceuticals, Inc. was $78,571,657,082.00 in 2018. The market capitalization for Regeneron Pharmaceuticals, Inc. was $78,249,006,000.00 in 2020. The market capitalization for Regeneron Pharmaceuticals, Inc. was $76,481,923,638.00 in 2015. The market capitalization for Regeneron Pharmaceuticals, Inc. was $74,949,056,000.00 in 2017. The market capitalization for Regeneron Pharmaceuticals, Inc. was $68,630,288,224.00 in 2014. The market capitalization for Regeneron Pharmaceuticals, Inc. was $65,662,716,273.00 in 2013. The market capitalization for Regeneron Pharmaceuticals, Inc. was $64,728,735,000.00 in 2016. The market capitalization for Regeneron Pharmaceuticals, Inc. was $59,607,291,613.00 in 2012. The market capitalization for Regeneron Pharmaceuticals, Inc. was $$102,405,000,000 in 2022. The gross revenue for Regeneron Pharmaceuticals, Inc. was $8,497,100,000.00 in 2020. The gross revenue for Regeneron Pharmaceuticals, Inc. was $6,557,600,000.00 in 2019. The gross revenue for Regeneron Pharmaceuticals, Inc. was $5,872,200,000.00 in 2017. The gross revenue for Regeneron Pharmaceuticals, Inc. was $5,145,600,000.00 in 2018. The gross revenue for Regeneron Pharmaceuticals, Inc. was $4,860,400,000.00 in 2016. The gross revenue for Regeneron Pharmaceuticals, Inc. was $4,103,728,000.00 in 2015. The gross revenue for Regeneron Pharmaceuticals, Inc. was $2,819,557,000.00 in 2014. The gross revenue for Regeneron Pharmaceuticals, Inc. was $2,104,745,000.00 in 2013. The gross revenue for Regeneron Pharmaceuticals, Inc. was $16,071,700,000.00 in 2021. The gross revenue for Regeneron Pharmaceuticals, Inc. was $1,378,477,000.00 in 2012. The gross revenue for Regeneron Pharmaceuticals, Inc. was $$12,173,000,000 in 2022. The gross margin for Regeneron Pharmaceuticals, Inc. was $41.03% in 2022. The days sales outstanding for Regeneron Pharmaceuticals, Inc. was 170 days in 2022. The days payable outstanding for Regeneron Pharmaceuticals, Inc. was 135 days in 2022. The days of inventory for Regeneron Pharmaceuticals, Inc. was $509 in 2022. The cost of goods sold (COGS) for Regeneron Pharmaceuticals, Inc. was 12.82% in 2022. The cost of goods sold (COGS) for Regeneron Pharmaceuticals, Inc. was $84,455,000.00 in 2012. The cost of goods sold (COGS) for Regeneron Pharmaceuticals, Inc. was $765,100,000.00 in 2019. The cost of goods sold (COGS) for Regeneron Pharmaceuticals, Inc. was $417,500,000.00 in 2018. The cost of goods sold (COGS) for Regeneron Pharmaceuticals, Inc. was $397,100,000.00 in 2017. The cost of goods sold (COGS) for Regeneron Pharmaceuticals, Inc. was $392,709,000.00 in 2015. The cost of goods sold (COGS) for Regeneron Pharmaceuticals, Inc. was $299,700,000.00 in 2016. The cost of goods sold (COGS) for Regeneron Pharmaceuticals, Inc. was $205,018,000.00 in 2014. The cost of goods sold (COGS) for Regeneron Pharmaceuticals, Inc. was $2,437,500,000.00 in 2021. The cost of goods sold (COGS) for Regeneron Pharmaceuticals, Inc. was $155,355,000.00 in 2013. The cost of goods sold (COGS) for Regeneron Pharmaceuticals, Inc. was $1,119,900,000.00 in 2020. The cost of goods sold (COGS) for Regeneron Pharmaceuticals, Inc. was $$1,560,000,000 in 2022. The cash to cash cycle time for Regeneron Pharmaceuticals, Inc. was 544 in 2022. The annual percentage growth rate of Regeneron Pharmaceuticals, Inc. was 0.24% in 2022. Regeneron Pharmaceuticals, Inc. in its benchmark peer group, had rank 4 for cash to cash cycle time in 2022. Regeneron Pharmaceuticals, Inc. in its benchmark peer group, had rank 4 days for days sales outstanding in 2022. Regeneron Pharmaceuticals, Inc. in its benchmark peer group, had rank 4 days for days of inventory in 2022. Regeneron Pharmaceuticals, Inc. in its benchmark peer group, had rank 3 for cost of goods sold as a percent of revenue in 2022. Regeneron Pharmaceuticals, Inc. in its benchmark peer group, had rank 2 for gross revenue in 2022. Regeneron Pharmaceuticals, Inc. in its benchmark peer group, had rank 1 for sales growth in 2022. Regeneron Pharmaceuticals, Inc. headquarters region is East. Regeneron Pharmaceuticals, Inc. has ticker symbol REGN. Regeneron Pharmaceuticals, Inc. has the following profile: Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.. Regeneron Pharmaceuticals, Inc. has primary indstury Biotechnology. Regeneron Pharmaceuticals, Inc. had a $$670,000,000 gap between actual performance and next performance rank for gross revenue in competitive benchmarking in 2022. Regeneron Pharmaceuticals, Inc. had Regeneron Pharmaceuticals, Inc., and Incyte, and Vertex Pharmaceuticals Incorporated, and Moderna benchmark peer companies for its SIC code in 2022. Regeneron Pharmaceuticals, Inc. had 442 days gap between actual performance and next performance rank for cash to cash in competitive benchmarking in 2022. Regeneron Pharmaceuticals, Inc. had 400 days gap between actual performance and next performance rank for days of inventory in competitive benchmarking in 2022. Regeneron Pharmaceuticals, Inc. had 3.93% gap between actual performance and next performance rank for gross margin in competitive benchmarking in 2022. Regeneron Pharmaceuticals, Inc. had 2.49% gap between actual performance and next performance rank for sales volatility in competitive benchmarking in 2022. Regeneron Pharmaceuticals, Inc. had 110 days gap between actual performance and next performance rank for days sales outstanding in competitive benchmarking in 2022. Regeneron Pharmaceuticals, Inc. had 11,851 number of employees in 2022. Regeneron Pharmaceuticals, Inc. had 0.36% gap between actual performance and next performance rank for cost of goods sold as a percent of revenue in competitive benchmarking in 2022. Regeneron Pharmaceuticals, Inc. had 0.00% gap between actual performance and next performance rank for sales growth in competitive benchmarking in 2022. Regeneron Pharmaceuticals, Inc. can reduce overall cost by $$458,000,000 by improving both COGS and SGA to next benchmark tier in 2022. Regeneron Pharmaceuticals, Inc. can reduce inventory with practices including SKU Reduction in 2022. Regeneron Pharmaceuticals, Inc. can reduce inventory with practices including Reduce Manufacturing Latency in 2022. Regeneron Pharmaceuticals, Inc. can reduce inventory with practices including Forecast Accuracy in 2022. Regeneron Pharmaceuticals, Inc. can reduce inventory with practices including Demand Shaping in 2022. Regeneron Pharmaceuticals, Inc. can reduce days sales outstanding with practices including in 2022. Regeneron Pharmaceuticals, Inc. can increase sales revenue by $$670,000,000 improving sales performance to next benchmark tier in 2022. Regeneron Pharmaceuticals, Inc. can increase revenue growth by $$0 by improving growth performance to next benchmark tier in 2022. Regeneron Pharmaceuticals, Inc. can increase overall revenue by $$670,000,000 by improving both growth and sales performance to next benchmark tier in 2022. Regeneron Pharmaceuticals, Inc. can increase days payables outstanding with practices including Strategic Sourcing in 2022. Regeneron Pharmaceuticals, Inc. can increase days payables outstanding by $870,000,000 days by increasing days payables outstanding to next benchmark tier in 2022. Regeneron Pharmaceuticals, Inc. can improve total financial performance by $$18,991,000,000 by improving revenue, costs, and working capital in 2022. Regeneron Pharmaceuticals, Inc. can decrease overall working capital by $$17,862,000,000 by improving inventory, payables and receivables to next benchmark tier in 2022. Regeneron Pharmaceuticals, Inc. can decrease inventory days by $13,340,000,000 days by reducing inventory days to next benchmark tier in 2022. Regeneron Pharmaceuticals, Inc. can decrease days sales outstanding by $3,652,000,000 days by reducing days sales outstanding to next benchmark tier in 2022. Regeneron Pharmaceuticals, Inc. can accelerate revenue growth practices including in 2022. 79 days was the measured advantage or top third performance level for days of inventory in Regeneron Pharmaceuticals, Inc.'s peer group in 2022. 7.90% was the measured superior or top ten performance level for cost of goods sold as a percent of revenue in Regeneron Pharmaceuticals, Inc.'s peer group in 2022. 68 days was the measured superior or top ten performance level for days of inventory in Regeneron Pharmaceuticals, Inc.'s peer group in 2022. 62 days was the measured advantage or top third performance level for cash to cash cycle time in Regeneron Pharmaceuticals, Inc.'s peer group in 2022. 60 days was the measured parity or middle performance level for days sales outstanding in Regeneron Pharmaceuticals, Inc.'s peer group in 2022. 52 days was the measured advantage or top third performance level for days sales outstanding in Regeneron Pharmaceuticals, Inc.'s peer group in 2022. 49.60% was the measured superior or top ten performance level for gross margin in Regeneron Pharmaceuticals, Inc.'s peer group in 2022. 47 days was the measured superior or top ten performance level for days sales outstanding in Regeneron Pharmaceuticals, Inc.'s peer group in 2022. 38.48% was the measured parity or middle performance level for sales volatility in Regeneron Pharmaceuticals, Inc.'s peer group in 2022. 34.48% was the measured advantage or top third performance level for sales volatility in Regeneron Pharmaceuticals, Inc.'s peer group in 2022. 25.42% was the measured superior or top ten performance level for sales volatility in Regeneron Pharmaceuticals, Inc.'s peer group in 2022. 12.46% was the measured parity or middle performance level for cost of goods sold as a percent of revenue in Regeneron Pharmaceuticals, Inc.'s peer group in 2022. 11.50% was the measured advantage or top third performance level for cost of goods sold as a percent of revenue in Regeneron Pharmaceuticals, Inc.'s peer group in 2022. 109 days was the measured parity or middle performance level for days of inventory in Regeneron Pharmaceuticals, Inc.'s peer group in 2022. 102 days was the measured parity or middle performance level for cash to cash cycle time in Regeneron Pharmaceuticals, Inc.'s peer group in 2022. 0.15% was the measured superior or top ten performance level for sales growth in Regeneron Pharmaceuticals, Inc.'s peer group in 2022. -157 days was the measured superior or top ten performance level for cash to cash cycle time in Regeneron Pharmaceuticals, Inc.'s peer group in 2022. -0.10% was the measured parity or middle performance level for sales growth in Regeneron Pharmaceuticals, Inc.'s peer group in 2022. -0.03% was the measured advantage or top third performance level for sales growth in Regeneron Pharmaceuticals, Inc.'s peer group in 2022. $48.98% was the measured advantage or top third performance level for gross margin in Regeneron Pharmaceuticals, Inc.'s peer group in 2022. $44.95% was the measured parity or middle performance level for gross margin in Regeneron Pharmaceuticals, Inc.'s peer group in 2022. $$16,864,000,000 was the measured superior or top ten performance level for gross revenue in Regeneron Pharmaceuticals, Inc.'s peer group in 2022. $$12,843,000,000 was the measured advantage or top third performance level for gross revenue in Regeneron Pharmaceuticals, Inc.'s peer group. $$10,552,000,000 was the measured parity or middle performance level for gross revenue in Regeneron Pharmaceuticals, Inc.'s peer group in 2022.